Endometriosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 18+ Companies and 20+ Therapies | DelveInsight

DelveInsight's "Endometriosis Pipeline Insight 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Endometriosis pipeline landscape. It covers the Endometriosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Endometriosis Pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Endometriosis Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Endometriosis Pipeline Outlook Report- https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Endometriosis Pipeline Report
• In May 2025, Organon and Co. conducted a Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
• In January 2025:- Organon and Co.- The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
• In January 2025:- AbbVie- A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain.
• DelveInsight's Endometriosis pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Endometriosis treatment.
• The leading Endometriosis Companies such as ObsEva, Jiangsu HengRui Medicine Co., Ltd., Hope Medicine (Nanjing) Co., Ltd., ValiRx, BCI Pharma, Mithra Pharmaceuticals, Debiopharm, Forendo Pharma Ltd, TiumBio, EpicentRx, Flightpath Biosciences, Antev and others.
• Promising Endometriosis Pipeline Therapies such as Triptorelin Embonate, Implantable gestrinone, SN132D, OG-6219, Elagolix, and others.

Discover how the endometriosis treatment paradigm is evolving. Access DelveInsight's in-depth Endometriosis Pipeline Analysis for a closer look at promising breakthroughs @ Endometriosis Clinical Trials and Studies- https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Endometriosis Emerging Drugs Profile

• HMI-115: Hope Medicine
HMI-115 is a first-in-class monoclonal antibody drug that is developed by Hope Medicine Inc. that targets the prolactin receptor, a novel mechanism implicated in various hormone-related conditions. Designed to modulate prolactin signaling, HMI-115 holds therapeutic potential across multiple indications, including endometriosis and androgenetic alopecia. By specifically blocking the prolactin receptor, it aims to address underlying disease mechanisms without disrupting the broader hormonal balance, offering a targeted and innovative approach to treatment. Currently, the drug is in Phase II stage of its clinical development for the treatment of Endometriosis.

• Merigolix: TiumBio
TU2670 is an oral GnRH antagonist that can bind to pituitary receptors to suppress estradiol hormone. The existing treatment GnRH agonists, lowers patient comfort levels as it's in an injection form and inhibits sex hormones to the level of menopause, resulting in serious side effects such as bone loss. TU2670 is an oral GnRH antagonist that only suppresses hormone levels to the level of efficacy, improving both side effects and ease of administration by oral. In addition, being a sex hormone control mechanism, it allows for indication expansion to precocious puberty, test-tube baby, infertility treatment, etc. Currently, the drug is in Phase II stage of its development for the treatment of Endometriosis.

• SHR7280: Jiangsu HengRui Medicine Co., Ltd
SHR7280 is an orally bioavailable Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration, GnRH antagonist SHR7280 competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. In females, this prevents the production of estrogen by the ovaries and may relieve symptoms from sex-hormone dependent diseases. Since SHR7280 reduces the occurrence of premature LH surge in females, premature ovulation is also prevented. Currently, the drug is in Phase I/II stage of its development for the treatment of Endometriosis.

The Endometriosis Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Endometriosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometriosis Treatment.
• Endometriosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Endometriosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometriosis market

Explore groundbreaking therapies and clinical trials in the Endometriosis Pipeline. Access DelveInsight's detailed report now! @ New Endometriosis Drugs- https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Endometriosis Companies
ObsEva, Jiangsu HengRui Medicine Co., Ltd., Hope Medicine (Nanjing) Co., Ltd., ValiRx, BCI Pharma, Mithra Pharmaceuticals, Debiopharm, Forendo Pharma Ltd, TiumBio, EpicentRx, Flightpath Biosciences, Antev and others.

Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Endometriosis Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Endometriosis Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Endometriosis Pipeline Report
• Coverage- Global
• Endometriosis Companies- ObsEva, Jiangsu HengRui Medicine Co., Ltd., Hope Medicine (Nanjing) Co., Ltd., ValiRx, BCI Pharma, Mithra Pharmaceuticals, Debiopharm, Forendo Pharma Ltd, TiumBio, EpicentRx, Flightpath Biosciences, Antev, and others.
• Endometriosis Therapies- Triptorelin Embonate, Implantable gestrinone, SN132D, OG-6219, Elagolix, and others.
• Endometriosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Endometriosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in endometriosis drug development? Find out in DelveInsight's exclusive Endometriosis Pipeline Report-access it now! @ Endometriosis Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Endometriosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Endometriosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Mid Stage Products (Phase II)
10. HMI-115: Hope Medicine
11. Early Stage Products (Phase I/II)
12. SHR7280: Jiangsu HengRui Medicine Co., Ltd
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Endometriosis Key Companies
17. Endometriosis Key Products
18. Endometriosis- Unmet Needs
19. Endometriosis- Market Drivers and Barriers
20. Endometriosis- Future Perspectives and Conclusion
21. Endometriosis Analyst Views
22. Endometriosis Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.